BioSpace News Archive

European Medicines Agency Validates Type II Variation for Astellas’ XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the European Medicines Agency (EMA) has validated its Type II variation for XTANDI® (enzalutamide) for the treatment of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with high-risk biochemical recurrence (BCR) who are unsuitable for salvage-radiotherapy.

September 12, 2023
·
9 min read
Biotech Beach

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - September 13, 2023

Crinetics Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering of 11,441,648 shares of its common stock at a price to the public of $30.59 per share.

September 12, 2023
·
5 min read
Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 mg Tablets (generic name: peficitinib hydrobromide) in Taiwan for the treatment of rheumatoid arthritis.

September 12, 2023
·
2 min read
Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

American Journal of Hematology recently published the study result of BTK inhibitor orelabrutinib in patients with relapsed or refractory Marginal Zone Lymphoma, which investigated the efficacy and safety of orelabrutinib in r/r MZL.

September 12, 2023
·
4 min read